fwd1509

FWD1509 is an orally bioavailable, irreversible small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR), including EGFR exon 20 insertion mutations, as well as other EGFR mutations such as exon 19 deletions, L858R substitutions in exon 21, and T790M resistance mutations. It also exhibits activity against HER2 mutations. The drug is being developed primarily for the treatment of non-small cell lung cancer (NSCLC) with these specific genetic alterations. Its mechanism involves blocking the function of mutant EGFR and HER2 kinases to inhibit tumor cell proliferation and survival[2][5][6].

Other names

FWD-1509 MSOHFWD1509 MSOHFWD 1509 MSOH